Quantcast
Parents Perceive Using Agave Nectar Placebo Are Better Than

Parents Perceive Using Agave Nectar, Placebo Are Better Than Doing Nothing For Cough In Kids

Provided by The JAMA Network Journals Pasteurized agave nectar and placebo were both perceived to be better by parents for treating nighttime cough and the resulting sleep difficulty in infants and toddlers than doing nothing at all, according...

Latest Clinical research Stories

2014-10-31 08:26:32

Conference Call Scheduled for Monday, November 3, 2014 at 10:00 a.m. Eastern time JERUSALEM, October 31, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to...

2014-10-31 08:26:08

SAN DIEGO, Oct. 31, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended September 30, 2014. Brian M. Culley, the Company's Chief Executive Officer, said: "The third quarter was productive for Mast. Consistent with prior guidance, our 388-patient pivotal Phase 3 study of MST-188 for sickle cell disease is on track to complete enrollment by the end of next year. We now have...

2014-10-31 08:25:25

FDA states that approval will not be final until Astagraf XL® exclusivity expires; Veloxis is appealing this decision HORSHOLM, Denmark, Oct. 31, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus® XR. FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL®. Veloxis...

2014-10-31 08:25:16

NEW YORK, Oct. 31, 2014 /PRNewswire/ -- Analyst Brief by Small Cap Traders. Tenax Therapeutics, Inc. (NASDAQ: TENX) an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus on oxygen delivery to tissue. It is currently developing Oxycyte(TM), a product which is a safe and effective oxygen carrier for use in surgical and similar medical situations. The Company's Oxycyte oxygen carrier product is a...

2014-10-30 23:10:48

DMG Productions explores the latest breakthroughs in health and medicine. Zug, Switzerland (PRWEB) October 30, 2014 PSI CRO (PSI) announced that they will be featured in an upcoming episode of Innovations with Ed Begley Jr, airing 1Q 2015, via Discovery Channel. Dates and show times TBA. We believe that PSI’s approach and performance addresses the biggest challenge in our industry. According to various sources, more than 90% of trials run behind schedule, costing sponsors millions in...

2014-10-30 23:08:29

DrugDev is sponsoring and providing speakers for the 13th Annual Partnerships in Clinical Trials Congress in Barcelona, 4-6 November. Five investigators and site staff who are members of the DrugDev Network will serve as key thought leaders in interactive and educational panels during the conference. LONDON and AUDUBON, PA (PRWEB) October 30, 2014 DrugDev is proud to be sponsoring and providing speakers for the 13th Annual Partnerships in Clinical Trials Congress in Barcelona, 4-6...

2014-10-30 16:29:19

LEXINGTON, Mass., Oct. 30, 2014 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today third quarter 2014 financial results, and provided other business updates. Sebelipase alfa for LAL Deficiency The company recently started the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for sebelipase alfa as a treatment for patients...

2014-10-30 16:29:12

-- Optimizes resources by leveraging shared-services -- HAYWARD, Calif., Oct. 30, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced a reorganization of its research and development (R&D) organizations and a prioritization of the project portfolios within the generic and brand businesses. As a result of the reorganization, the generic R&D organization will be responsible for early stage product development and analytical functions for all Impax products,...

2014-10-30 12:30:09

PITTSBURGH, Oct. 30, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Nevirapine Extended-release tablets, 400 mg, which is the generic version of Boehringer Ingelheim's Viramune XR(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection in adults and in children six to...

2014-10-30 12:29:51

Clinical-grade software platform facilitates exchange of expertise among clinics, academic medical centers BOSTON and BETHESDA, Md., Oct. 30, 2014 /PRNewswire/ -- Cartagenia, a leader in providing genetic labs and clinicians with software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today the successful launch of a software platform for genetic variant assessment and reporting within the National Institutes of...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.